Home page Home page

Yentreve
duloxetine

Package leaflet: information for the user


YENTREVE 40 mg hard gastro-resistant capsules YENTREVE 20 mg hard gastro-resistant capsules Duloxetine (as hydrochloride)


Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

antidepressant


If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away.

image

You may find it helpful to tell a relative or close friend that you are depressed or have an anxiety disorder, and ask them to read this leaflet. You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behaviour.


Children and adolescents under 18 years of age

YENTREVE should not be used for children and adolescents under 18 years. Also, you should know that patients under 18 have an increased risk of side-effects such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behaviour and anger) when they take this class of medicines. Also, the long-term safety effects concerning growth, maturation, and cognitive and behavioural development of YENTREVE in this age group have not yet been demonstrated.


Other medicines and YENTREVE

Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.


The main ingredient of YENTREVE, duloxetine, is used in other medicines for other conditions:


Reporting of side effects


If you get any side effects, talk to your doctor of pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.


  1. How to store YENTREVE


    Keep this medicine out of the sight and reach of children.


    Do not use this medicine after the expiry date which is stated on the carton. Store in the original package to protect from moisture. Do not store above 30°C.

    Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away of medicines you no longer use. These measures will help to protect the environment.


  2. Contents of the pack and other information What YENTREVE contains

The active substance is duloxetine.

Each capsule contains 20 or 40 mg of duloxetine (as hydrochloride).


The other ingredients are:

Capsule content: hypromellose, hypromellose acetate succinate, sucrose, sugar spheres, talc, titanium dioxide (E171), triethyl citrate (See end of section 2 for further information on sucrose).

Capsule shell: gelatin, sodium lauryl sulfate, titanium dioxide (E171), indigo carmine (E132), red iron oxide and yellow iron oxide, edible black ink.

Edible ink: synthetic black iron oxide (E172), propylene glycol, shellac.


What YENTREVE looks like and contents of the pack

YENTREVE is a hard gastro-resistant capsule. Each capsule of YENTREVE contains pellets of duloxetine hydrochloride with a covering to protect them from stomach acid.


YENTREVE is available in 2 strengths: 20 and 40 mg.

The 40 mg capsules are orange and blue and are printed with ’40 mg’ and the code ‘9545’. The 20 mg capsules are blue and are printed with ’20 mg’ and the code ‘9544’.


YENTREVE 40 mg is available in packs of 28, 56, 98, 140 and 196 (2 x 98) capsules.

YENTREVE 20 mg is available in packs of 28, 56 and 98 capsules.


Not all pack sizes may be marketed.


Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder: Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.

Manufacturer: Lilly S.A., Avda. De la Industria, 30, 28108 Alcobendas, Madrid, Spain.


For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:


België/Belgique/Belgien

Eli Lilly Benelux S.A./N.V. Tél/Tel: + 32-(0)2 548 84 84

Lietuva

Eli Lilly Lietuva

Tel. +370 (5) 2649600


България

ТП "Ели Лили Недерланд" Б.В. - България тел. + 359 2 491 41 40

Luxembourg/Luxemburg Eli Lilly Benelux S.A./N.V. Tél/Tel: + 32-(0)2 548 84 84


Česká republika

Eli Lilly ČR, s.r.o.

Tel: + 420 234 664 111

Magyarország

Lilly Hungária Kft. Tel: + 36 1 328 5100


Danmark

Eli Lilly Danmark A/S Tlf: +45 45 26 60 00

Malta

Charles de Giorgio Ltd. Tel: + 356 25600 500


Deutschland

Lilly Deutschland GmbH Tel. + 49-(0) 6172 273 2222

Nederland

Eli Lilly Nederland B.V. Tel: + 31-(0) 30 60 25 800

Eesti

Eli Lilly Nederland B.V. Tel: +372 6 817 280

Norge

Eli Lilly Norge A.S Tlf: +47 22 88 18 00


Ελλάδα

ΦΑΡΜΑΣΕΡΒ-ΛΙΛΛΥ Α.Ε.Β.Ε. Τηλ: +30 210 629 4600

Österreich

Eli Lilly Ges.m.b.H. Tel: + 43-(0) 1 711 780


España

Spaly Bioquímica, S.A. Tel: + 34-91 623 17 32

Polska

Eli Lilly Polska Sp. z o.o. Tel: +48 22 440 33 00


France

Lilly France

Tél: +33-(0) 1 55 49 34 34

Portugal

Lilly Portugal - Produtos Farmacêuticos, Lda Tel: + 351 21-4126600


Hrvatska

Eli Lilly Hrvatska d.o.o. Tel: +385 1 2350 999

România

Eli Lilly România S.R.L. Tel: + 40 21 4023000


Ireland

Eli Lilly and Company (Ireland) Limited Tel: +353-(0) 1 661 4377

Slovenija

Eli Lilly farmacevtska družba, d.o.o.

Tel: +386 (0)1 580 00 10


Ísland

Icepharma hf.

Sími + 354 540 8000

Slovenská republika Eli Lilly Slovakia s.r.o. Tel: + 421 220 663 111


Italia

Eli Lilly Italia S.p.A. Tel: + 39- 055 42571

Suomi/Finland

Oy Eli Lilly Finland Ab Puh/Tel: +358-(0) 9 85 45 250


Κύπρος

Phadisco Ltd

Τηλ: +357 22 715000

Sverige

Eli Lilly Sweden AB Tel: + 46-(0)8 7378800


Latvija

Eli Lilly (Suisse) S.A Pārstāvniecība Latvijā

Tel: + 371 67364000

United Kingdom (Northern Ireland) Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4377


This leaflet was last revised in


u.